| scholarly article | Q13442814 |
| P50 | author | David R. Boulware | Q39519469 |
| P2093 | author name string | Matthew Merry | |
| P2860 | cites work | Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis | Q21144604 |
| Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome | Q24630287 | ||
| Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS | Q29617372 | ||
| Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. | Q34020746 | ||
| Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis | Q34024416 | ||
| Cost-effective diagnostic checklists for meningitis in resource-limited settings | Q34331360 | ||
| Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Updated Guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseas | Q34407741 | ||
| Long term 5-year survival of persons with cryptococcal meningitis or asymptomatic subclinical antigenemia in Uganda | Q34516367 | ||
| Epidemiology of cryptococcal meningitis in the US: 1997-2009. | Q34606681 | ||
| Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984-2008. | Q36661756 | ||
| A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis | Q37182083 | ||
| Amphotericin B formulations: a comparative review of efficacy and toxicity | Q38111293 | ||
| Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries | Q38111887 | ||
| Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis | Q38869006 | ||
| Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda | Q38869763 | ||
| Combination antifungal therapy for cryptococcal meningitis | Q41924502 | ||
| Epidemiology of bacterial meningitis in the USA from 1997 to 2010: a population-based observational study | Q42202691 | ||
| Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety | Q43035140 | ||
| Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group | Q44474075 | ||
| Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis | Q46248271 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | United States of America | Q30 |
| infectious disease | Q18123741 | ||
| meningitis | Q48143 | ||
| 5-fluorocytosine | Q238490 | ||
| cryptococcal meningitis | Q18967011 | ||
| P304 | page(s) | 1564-8 | |
| P577 | publication date | 2016-06-15 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | Cryptococcal Meningitis Treatment Strategies Affected by the Explosive Cost of Flucytosine in the United States: A Cost-effectiveness Analysis | |
| P478 | volume | 62 |
| Q92082976 | Diagnosis and Management of Central Nervous System Cryptococcal Infections in HIV-Infected Adults |
| Q61798536 | Evaluation of a national cryptococcal antigen screening program for HIV-infected patients in Uganda: A cost-effectiveness modeling analysis |
| Q38776044 | Influence of drug class and healthcare setting on systemic antifungal expenditures in the United States, 2005-15. |
| Q92251781 | Mortality by cryptococcosis in Brazil from 2000 to 2012: A descriptive epidemiological study |
| Q57177336 | Present and Future Therapy of Infections |
| Q47304536 | Prevalence, healthcare resource utilization and overall burden of fungal meningitis in the United States |
| Q38851467 | Recent advances in AIDS-related cryptococcal meningitis treatment with an emphasis on resource limited settings. |
| Q92583417 | The combination of tamoxifen with amphotericin B, but not with fluconazole, has synergistic activity against the majority of clinical isolates of Cryptococcus neoformans |
| Q39189670 | The current treatment landscape: other fungal diseases (cryptococcosis, fusariosis and mucormycosis). |
| Q97883052 | What Is the Most Appropriate Induction Regimen for the Treatment of HIV-Associated Cryptococcal Meningitis When the Recommended Regimen Is Not Available? Evidence From a Network Meta-Analysis |
Search more.